

Cost-effectiveness of remdesivir and dexamethasone for COVID-19 treatment in South Africa

Running Title: Cost-effectiveness of remdesivir and dexamethasone in South Africa

Youngji Jo^a, Lise Jamieson^b, Ijeoma Edoaka^c, Lawrence Long^{b,d}, Sheetal Silal^{e,f}, Juliet R.C. Pulliam^g, Harry Moultrie^h, Ian Sanne^b, Gesine Meyer-Rath^{b,d}, Brooke E Nichols^{b,d*}

- a. Section of Infectious Disease, Department of Medicine, Boston Medical Center, Boston, MA, USA
- b. Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- c. SAMRC Centre for Health Economics and Decision Science-PRICELESS SA, School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, South Africa
- d. Department of Global Health, School of Public Health, Boston University, Boston, MA, USA
- e. Modelling and Simulation Hub, Africa, Department of Statistical Sciences, University of Cape Town, Cape Town, South Africa
- f. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
- g. South African DSI-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa
- h. Division of the National Health Laboratory Service, National Institute for Communicable Diseases (NICD), Johannesburg, South Africa

Address for correspondence: Brooke Nichols, Boston University School of Public Health, 801 Massachusetts Ave, Crosstown Center 3rd Floor, Boston, MA, USA; email: brooken@bu.edu; phone: +1-617-358-2403

Alternate corresponding author: Youngji Jo, Section of Infectious Disease, Department of Medicine, Boston Medical Center, Boston, MA, USA; email: Youngji.jo@bmc.org; phone: +1-443-800-1626

Words: 2384/3000

40-word summary of article's main point: The use of remdesivir and dexamethasone for treatment of severe COVID-19 in South Africa is likely to be cost-saving relative to standard care. Enabling access to these medications should be prioritize to improve patient outcomes and reduce total costs.

38 **Abstract—249/250**

39

40 **Background**

41 South Africa recently experienced a first peak in COVID-19 cases and mortality. Dexamethasone and remdesivir
42 both have the potential to reduce COVID-related mortality, but their cost-effectiveness in a resource-limited
43 setting with scant intensive care resources is unknown.

44

45 **Methods**

46 We projected intensive care unit (ICU) needs and capacity from August 2020 to January 2021 using the South
47 African National COVID-19 Epi Model. We assessed cost-effectiveness of 1) administration of dexamethasone to
48 ventilated patients and remdesivir to non-ventilated patients, 2) dexamethasone alone to both non-ventilated
49 and ventilated patients, 3) remdesivir to non-ventilated patients only, and 4) dexamethasone to ventilated
50 patients only; all relative to a scenario of standard care. We estimated costs from the healthcare system
51 perspective in 2020 USD, deaths averted, and the incremental cost effectiveness ratios of each scenario.

52

53 **Results**

54 Remdesivir for non-ventilated patients and dexamethasone for ventilated patients was estimated to result in
55 1,111 deaths averted (assuming a 0-30% efficacy of remdesivir) compared to standard care, and save \$11.5
56 million. The result was driven by the efficacy of the drugs, and the reduction of ICU-time required for patients
57 treated with remdesivir. The scenario of dexamethasone alone to ventilated and non-ventilated patients
58 requires additional \$159,000 and averts 1,146 deaths, resulting in \$139 per death averted, relative to standard
59 care.

60

61 **Conclusions**

62 The use of dexamethasone for ventilated and remdesivir for non-ventilated patients is likely to be cost-saving
63 compared to standard care. Given the economic and health benefits of both drugs, efforts to ensure access to
64 these medications is paramount.

65

66

67 **Keywords:** SARS-CoV-2; COVID-19; mathematical model; hospital bed capacity; intensive care; cost-effectiveness;
68 dexamethasone; remdesivir

69

70

71

72

73

74

75

76

77

78

79 Introduction

80 As of September 2020, there were over 29 million confirmed SARS-CoV-2 infections worldwide, and over
81 939,000 reported COVID-19 associated deaths.(1) South Africa has the 8th highest number of confirmed cases
82 worldwide with more than 653,000 confirmed infections and 16,000 confirmed COVID-19 deaths.(2) During the
83 surge in cases, intensive care unit (ICU) capacity was reportedly breached in some locations and much-needed
84 oxygen supplies were running low.(3) While increased mortality is associated with several individual-level factors
85 including older age, male sex, and pre-existing comorbidities, systems-level factors such as being admitted to a
86 hospital with fewer ICU beds also play a role.(4) Considering inter-hospital variation in treatment and outcomes,
87 the mortality rate among those in ICU has ranged between 40%-50%.(4-6) To mitigate the mortality impact of
88 COVID-19 in South Africa and other low- and middle-income countries with scant intensive care capacity, efforts
89 to reduce mortality amongst the more severe cases in ICU are paramount. Recently, two therapeutic agents,
90 remdesivir and dexamethasone, have been demonstrated in randomized clinical trials to reduce COVID-related
91 mortality.(7, 8)

92
93 Dexamethasone has been shown to decrease mortality by 35% (95% confidence interval [CI]: 18% to 49%) and
94 20% (95% CI: 8% to 30%) in ventilated ICU patients and non-ventilated patients with oxygen respectively and has
95 shown no clear evidence regarding its impact on recovery time,(8) while remdesivir has been shown to decrease
96 mortality by 30% (95% CI: -4% to 53%) and reduce recovery time from 15 (95% CI: 13-19) to 11 (95% CI:9-12)
97 days amongst ICU patients who are not ventilated.(7) In low- and middle- income countries, not only is ICU
98 capacity limited, but so are budgets for COVID-related care. There has been an additional budget allocation of
99 \$1.14 billion for the health response to COVID-19 in South Africa(9), though this budget does not yet include
100 remdesivir or dexamethasone. We therefore conducted a cost-effectiveness analysis to determine the
101 incremental cost per death averted of providing dexamethasone and remdesivir relative to the standard care of
102 critically ill patients in South African ICUs from a health systems perspective. The cost-effectiveness of these
103 regimens is going to become increasingly important for possible eventuality of a COVID-19 resurgence in South
104 Africa, in order to ensure improved ICU capacity and patient outcomes during a future wave.

105 106 Methods

107
108 Using the South African National COVID-19 Epidemiology Model (NCEM)(10) and government data on the
109 number of currently available ICU beds in the public and private sector by province(11), we projected the
110 number of people requiring ICU admission and total ICU person days by province by month between August
111 2020 and January 2021. We then projected costs and COVID-related mortality for four scenarios: 1)
112 dexamethasone administered to ventilated patients (i.e. in an advanced stage of disease illness) and remdesivir
113 to non-ventilated patients (i.e. to those receiving supplemental oxygen as in an earlier stage of disease illness), 2)
114 dexamethasone alone to both non-ventilated and ventilated patients, 3) remdesivir to non-ventilated patients
115 only, and 4) dexamethasone to ventilated patients only; all relative to standard of ICU care (without remdesivir
116 and dexamethasone).

117
118 Our effectiveness measure was expressed as COVID-19 deaths averted. The mortality impact for all patients in
119 ICU between August 2020 and January 2021 was estimated by applying the treatment impact of remdesivir and

120 dexamethasone on mortality from the results of recent randomized controlled trials (7, 8) and impact on
121 mortality that remdesivir could have through decreasing the average length of stay of patients (from 15 to 11
122 days), when ICU capacity is expected to be breached.(7) (Table 1) Based on South African COVID-19
123 hospitalisation data and treatment guidelines(12), we assumed that 42% of patients in ICU require mechanical
124 ventilation, while the remaining (58%) patients do not yet require mechanical ventilation (though they might
125 require supplementary oxygen). A course of dexamethasone (oral/intravenous administration) is assumed to be
126 10 days long, and a course of remdesivir (intravenous) is assumed to be five days long.

127
128 We estimated resource use from the perspective of the provider, the South African healthcare system, for all
129 ICU-days accrued by COVID-19 patients from August 2020 and January 2021 for each scenario. (Note that since
130 COVID-19 patients will be accommodated in both the private and public sector, depending on need and
131 availability, and contracting arrangements towards that end were in place in all provinces at the time of writing,
132 we combined both sectors for the purpose of this analysis.) We calculated health system operational cost
133 (excluding drug costs) based on the latest NCEM outputs (i.e. required total ICU beds and days) with and without
134 remdesivir and/or dexamethasone. We used an ICU cost per person day of \$1,128 (\$665-\$1,172) based on an
135 ingredients-based costing analysis including capital equipment, current South African ICU staffing norms and
136 salaries, and overhead costs representative of South Africa public hospital settings.(13) Capital assets (e.g.
137 ventilators) were annualized based on the relevant years of useful life (e.g. 10 years) and discounted at a 5%
138 annual rate based on the South Africa pharmacoeconomic guidelines.(14)

139
140 For the scenarios including novel therapeutics, we assumed the additional cost of a full course of remdesivir
141 (\$55 per 100mg IV, corresponding to \$330 per patient course)(15) and/or dexamethasone (\$3.13 per 4mg,
142 corresponding to \$31 per patient course)(16), for the respective scenarios that include these therapeutics.
143 (Table 2) Costs were converted from South African Rands (ZAR) to US dollars (USD) at the average exchange rate
144 over the period August 2020 and January 2021 (1 USD = 16.95 ZAR).(17) Incremental cost effectiveness ratios
145 were calculated as the incremental cost in 2020 USD of each therapeutic scenario over standard care per death
146 averted .

147
148 We performed one-way sensitivity analyses on all model parameters to describe the robustness of the primary
149 results expressed as incremental cost per death averted to uncertainty in individual model parameters. Under
150 our baseline assumptions, we also investigated whether and to what extent the benefit of a reduction in the
151 length of ICU stay with remdesivir may differ by either assuming 1) capacity being breached for all months in all
152 provinces vs 2) capacity never being breached. To explore the combined effect of uncertainty in our model
153 parameters, we conducted a probabilistic sensitivity analysis (PSA). All model parameter values were randomly
154 sampled over pre-specified distributions (Table 2) and 1,000 simulations were performed to produce cost-
155 effectiveness acceptability curves. The model was constructed in Microsoft Excel using an Excel Visual Basic
156 Macro to run the simulations.

157 158 **Results**

159
160 In South Africa, there were a reported 3,318 public (1,178) and private (2,140) ICU beds available in total (11)
161 and it was reported that only 70% (2,309 beds) were available for COVID patients as of 31 May 2020 (18). The

162 estimated total health systems operation cost of COVID-19 related ICU care in South African excluding drugs
163 during August 2020 and January 2021 is \$83.9 million without remdesivir (standard care) and \$71.4 million with
164 remdesivir due to the reduction in required total ICU person days. In terms of drug costs, we estimated
165 \$983,000 required for remdesivir administered to non-ventilated patients, \$67,000 for dexamethasone
166 administered to ventilated patients, or \$159,000 when dexamethasone is administered to all patients in the ICU
167 across all six months.

168
169 Overall, the scenario with a combination of remdesivir and dexamethasone can save \$11.5 million relative to
170 standard care and avert a total of 1,111 deaths (Table 3). Of this, 473 deaths are averted due to remdesivir
171 (assuming 30% mortality reduction due to remdesivir use), and 638 deaths averted due to dexamethasone on
172 mortality. Similarly, the scenario with remdesivir to non-ventilated patients only can save \$11.5 million relative
173 to standard care but will result in fewer total deaths averted (473) compared to the scenario where both
174 dexamethasone and remdesivir are used. The scenario with dexamethasone alone to ventilated and non-
175 ventilated patients requires additional \$159,048 but avert 1,146 deaths (\$139 per death averted) relative to
176 standard care. Therefore, should remdesivir become available, the use of remdesivir in combination with
177 dexamethasone is recommended given the substantially greater cost saving for a similar health benefit.

178
179 Our sensitivity analyses reveal that the uncertainty in the number of months ICU capacity is breached, and the
180 efficacy of remdesivir and dexamethasone have the greatest impact on the ICER (Figure 1). For example, if ICU
181 capacity is expected to be breached in all months and in all provinces, a scenario with remdesivir and
182 dexamethasone combination will result in an additional drug costs of \$9.3 million but will avert 6,562 deaths,
183 resulting \$1,421 per death averted; but if the ICU capacity is not expected to be breached at all, then the
184 remdesivir and dexamethasone combination scenario can save up to \$12 million (mainly due to the reduced
185 total ICU days and health systems costs by remdesivir) and avert 659 deaths relative to standard care. If
186 remdesivir reduces mortality by 30%, the scenario of remdesivir and dexamethasone combination will avert
187 between 1,112 and 14,655 deaths (\$636 per death averted) by the zero to the full (6) months across all
188 provinces of ICU capacity being breached, respectively. The results of the PSA, displayed in the cost-
189 effectiveness acceptability curves shows the probability of the intervention being cost-effective under different
190 willingness to pay thresholds (Figure 2). For example, at a willingness to pay threshold of \$1,000 per death
191 averted, it is highly likely that the use of remdesivir and dexamethasone combined for critically ill COVID-19
192 patients in ICU will be cost effective (almost 100% of simulation estimates fell below the threshold) in various
193 treatment scenarios compared to standard care in South Africa. The scenarios that include remdesivir show
194 almost 50% of simulations fall below the cost saving threshold (i.e. incremental cost is less than 0) with more
195 variability, mainly due to the uncertainty associated with the reduction in ICU days during non-breached months.
196 Additionally, in the event that the mortality impact of remdesivir is 0% instead of 30%, the cost-effectiveness
197 estimates do not change due to the substantial cost savings from reducing inpatient days.

198 199 **Discussion**

200
201 This analysis explores whether and to what extent remdesivir and dexamethasone might be considered cost-
202 effective for critically ill COVID-19 patients in the context of a declining COVID-19 pandemic in South Africa. We
203 find that a combination of remdesivir for non-ventilated patients and dexamethasone for ventilated patients is

204 expected to maximize the number of deaths averted, and save the government of South Africa \$11.5 million
205 between August 2020 and January 2021. The results extend earlier findings regarding the mortality impact of
206 remdesivir alone by reducing length of ICU stay and treating more COVID-19 patients in the ICU.(10) However,
207 the months assumed for that early analysis included during the first peak of COVID-19 cases when resources
208 were severely constrained. The present analysis is focused on the subsequent six months over which we expect
209 the pandemic to continue to wane. This analysis demonstrates that remdesivir is likely to generate cost-savings
210 and can offset the additional drug costs of dexamethasone to ventilated patients. This analysis therefore
211 supports efforts to ensure access to remdesivir and dexamethasone even as COVID-19 epidemics wane – in
212 order to save both lives and costs.

213

214 The number of deaths averted due to increasing ICU capacity in this analysis differ from our previous
215 findings.(10) This is due to two factors. First, in this analysis we are assuming that only some patients in ICU
216 receive remdesivir, instead of all patients. Second, the most recent set of model predictions from the NCEM
217 project a waning epidemic in which ICU capacity is seldom breached. This differs previous projections that
218 included the months of peak COVID-19 epidemic in South Africa (June-August 2020). This has resulted in much
219 fewer deaths averted projected due to increasing ICU capacity.

220

221 Our analysis has several limitations. Firstly, the number of months ICU capacity is breached is influenced by the
222 interplay between epidemic conditions and policy choices (which can affect ICU admission of other diseases).(19)
223 As this will have different implications for costs and health outcomes in each scenario, it will be important to
224 consider regional heterogeneity in epidemic conditions, health system capacity and willingness to pay in order
225 to guide optimal treatment strategies. Second, we did not consider potential changes in the clinical course with
226 disease progression nor change of distribution of disease severity among the patient population over time.
227 Importantly, efficacy of remdesivir and dexamethasone in preventing mortality can be influenced by several
228 factors – time of treatment initiation after symptom onset (20, 21), age (22), comorbidities(23), potential
229 adverse events(24), and use of other medications(25, 26). As additional treatment options become available(27),
230 it would also be important to collect more data on the duration of illness and its relationship to the outcome
231 (both in terms of efficacy and safety)(24) and conduct more detailed analyses considering patient population
232 characteristics, change of epidemic curves and local health system capacity, that can guide an optimal treatment
233 strategy in a resource constrained setting. Third, our cost data does not include additional costs associated with
234 adverse events management and also may not fully incorporate potential economies of scale due to increased
235 volume of patients within a given ICU capacity. We also did not differentiate costs or financial implication
236 between public and private hospitals. While this may change the point estimate of our results, it is unlikely to
237 alter our conclusions. Continued efforts to develop clinical practice guideline (i.e. who to treat, where, how and
238 when)(28) to reduce length of ICU stay, for patients in ICU with COVID-19 (29, 30) could further improve clinical
239 benefits and cost-effectiveness. Finally, given that cost-savings observed with remdesivir is driven by months
240 when ICU capacity is not breached, the value for money of remdesivir may increase during the next phase of the
241 pandemic as new cases decline and the pressure on ICUs eases. Given great uncertainty in making long-term
242 projections into 2021, the time horizon for this study was limited to latest projections from the NCEM.

243

244 **Conclusion**

245

246 To conclude, treatment with remdesivir for non-ventilated patients and dexamethasone for ventilated patients
247 will maximize lives saved and is predicted to save \$11.5 million between August 2020 and January 2021. The
248 results were strongly driven by the efficacy of the drugs, and the reduction of ICU-time required for patients
249 treated with remdesivir. We therefore recommend that future studies collect additional data on mortality
250 impact stratified by disease severity and care condition in South Africa to further refine cost-effectiveness
251 analyses and guide implementation. This analysis strongly supports ensuring access to remdesivir and
252 dexamethasone to save costs and lives in South Africa.

253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287

288 **Table 1. Comparison between remdesivir and dexamethasone as COVID-19 treatment in South Africa**

		Remdesivir	Dexamethasone
Regimen (14)		Antiviral: 200 mg IV loading dose following by 100 mg IV daily for up to 5 days for patients who are hospitalized.	Steroid: 6 mg PO / IV for up to 10 days for patients with an oxygen requirement and/or requiring mechanical ventilation.
Clinical trial (7,8)		National Institute of Allergy and Infectious Diseases (NIAID) Clinical Trial	Oxford RECOVERY trial
Clinical outcome (7,8)	Median time to recovery	From 15 (13–19) days in standard care to 11 (9–12) days with Remdesivir	N/A
	Overall (Hazard ratio)	RR 0.70 (95% CI 0.47–1.04)*	RR 0.83 (95% CI 0.74–0.92)
	Patients not receiving oxygen	RR 1.38 (95% CI 0.94–2.03)	RR 1.22 [95% CI 0.93 to 1.61]
	Patients receiving oxygen	RR 1.47 (95% CI 1.17–1.84)	RR 0.80 [95% CI 0.70 to 0.92]*
	Patients receiving high-flow oxygen or noninvasive mechanical ventilation	RR 1.20 (95% CI 0.79–1.81)	
Patients receiving mechanical ventilation	RR 0.95 (95% CI 0.64–1.42)	RR 0.65 [95% CI 0.51 to 0.82]*	
Availability (31)(32)		Possibly in short supply	Currently in market
Any adverse events (24, 33)		Remdesivir vs placebo: 66% vs. 64% for any group, 8% vs. 14% for patients receiving oxygen	N/A

*Asterisk represents the mortality reduction rates used for remdesivir and dexamethasone in the model.

289
290
291
292

Table 2. Key input parameters

Patient disease status in ICU	Base	Low	High	Distribution	Source
% of patients requiring mechanical ventilation	42%	34%	49%	Triangular	(7, 10,11)
Days of hospitalization for non-ventilated patients	15	7	18	Triangular	
Days of hospitalization for ventilated patients	19	15	32	Triangular	
Efficacy	Base	Low	High	Distribution	Source
Reduced days of hospitalization with remdesivir (from 15 days to 11 days)	4	2	6	Triangular	(7)
Mortality if those additional patients receive ICU care	50%	40%	85%	Beta	(10)
Mortality if those additional patients do not receive ICU care	90%	85%	100%	Beta	(10)
Mortality rate reduction for earlier stage (non-ventilated) patients due to remdesivir	30%	0%	53%	Beta	(7)
Mortality rate reduction for later stage (ventilated) patients due to dexamethasone	35%	18%	49%	Beta	(8)
Mortality rate reduction for earlier stage (non-ventilated) patients due to dexamethasone	20%	8%	30%	Beta	(8)
Cost inputs	USD	Low	High	Distribution	Source
Health system operation cost in ICU per person day	\$1,128	\$665	\$1,172	Gamma	(13)
Cost of remdesivir regimen (200 mg IV loading dose following by 100 mg IV daily for a maximum of 5 days)	\$330	\$99	\$330	Gamma	(15)
Cost of dexamethasone regimen (6 mg PO / IV for up to 10 days)	\$31	\$16	\$47	Gamma	(16)

293
294
295
296
297

Table 3. Total costs, health outcome, and incremental cost effectiveness ratios of COVID-19 treatment scenarios in South Africa from August 2020 - January 2021 (with 95% uncertainty ranges reported as the 2.5th and 97.5th percentiles of the corresponding distributions)


Scenarios	Total costs	Deaths averted			Cost per death averted
		Remdesivir	Dexamethasone	Total	<i>30% reduction in mortality of remdesivir</i>
Standard care	\$83,937,000 (\$43,612,000 \$104,632,000)	ref	ref	ref	ref
Dexamethasone to non-ventilated and ventilated patients	\$84,096,000 (\$44,260,000 \$104,497,000)	n/a	1,146 (572 – 1,863)	1,146 (572 – 1,863)	\$139 (-\$51, \$350)
Dexamethasone to ventilated patients only	\$84,003,000 (\$44,24,000 \$104,326,000)	n/a	638 (227 – 1,140)	638 (227 – 1,140)	\$104 (-\$36, \$336)
Dexamethasone to ventilated patients & Remdesivir to non-ventilated patients	\$72,465,000 (\$44,100,000 \$106,437,000)	473* (29– 1,293)	638 (227 – 1,140)	1,111 (239 – 2,027)	Cost saving
Remdesivir to non-ventilated patients only	\$72,399,000 (\$44,074,000 \$106,310,000)	473* (29– 1,293)	n/a	473 (2 – 1,293)	Cost saving

298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322

*The number represents death averted by remdesivir assuming 30% reduction in mortality. It will be 9 (by decreasing the average length of stay of patients when ICU capacity is expected to be breached), if 0% reduction in mortality of remdesivir is assumed.

323
324
325
326
327


Figure 1. One-way sensitivity analyses of incremental cost effectiveness ratio comparison between a using remdesivir for non-ventilated ICU patients plus dexamethasone for ventilated patients compared to standard care (assuming 30% efficacy of remdesivir)




328
329
330
331
332
333
334
335
336
337
338
339
340

Figure 2. Cost-effectiveness plane and acceptability curves of the four dexamethasone and remdesivir treatment scenarios compared to standard care

A. Cost effectiveness plane



B. Cost effectiveness acceptability curves



*Variation of incremental cost in simulation output for the scenarios with dexamethasone is much narrower than the outputs for the scenarios including remdesivir because the incremental costs (relative to standard care) is only caused by drug costs (without change in length of ICU stay by the given number of ICU beds) and days by whereas the incremental cost of the scenarios with remdesivir (relative to standard care) is caused by both health system costs (due to the reduced length of ICU stay) and drug costs.

References

1. Roser M, Ritchie H, Ortiz-Ospina E, Hasell J. Coronavirus Pandemic (COVID-19) OurWorldInData.org2020 [Available from: <https://ourworldindata.org/coronavirus>.
2. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). <https://coronavirus.jhu.edu/map.html> Accessed July 20, 2020.
3. Magome M. Oxygen already runs low as COVID-19 surges in South Africa. The Washington Post. 2020 10 July 2020.
4. Kim L, Garg S, O'Halloran A, Whitaker M, Pham H, Anderson EJ, et al. Risk Factors for Intensive Care Unit Admission and In-hospital Mortality among Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). Clin Infect Dis. 2020.
5. Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. JAMA Intern Med. 2020.
6. Armstrong RA, Kane AD, Cook TM. Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies. Anaesthesia. 2020.
7. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med. 2020.
8. Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020.
9. Statement by President Cyril Ramaphosa on South Africa's response to the coronavirus pandemic, Union Buildings, Tshwane. April 23, 2020. <http://www.presidency.gov.za/speeches/statement-president-cyril-ramaphosa-south-africa%27s-response-coronavirus-pandemic%2C-union-buildings%2C-tshwane>
10. Nichols BE, Jamieson L, Zhang SRC, Rao GA, Silal S, Pulliam JRC, et al. The role of remdesivir in South Africa: preventing COVID-19 deaths through increasing ICU capacity. Clin Infect Dis. 2020.
11. MASHA, HE2RO, SACEMA. Estimating cases for COVID-19 in South Africa: Long-term national projections. South Africa: National Institute of Communicable Diseases; 2020.
12. National Institute for Communicable Disease. COVID-19 Guidelines. <https://www.nicd.ac.za/diseases-a-z-index/covid-19/covid-19-guidelines/>
13. Edoaka I et al. Inpatient Care Costs of COVID-19 in South Africa's Public Healthcare System. Under review.
14. Department of Health. Medicines and Related Substances Act (101/1965) Regulations relating to a transparent pricing system for medicines and scheduled substances: Publication of guidelines for pharmacoeconomic submissions. Pretoria: Government Gazette; February 2013.
15. Business Insider South Africa. The US is buying Covid-19 drug remdesivir like crazy. A generic is coming to SA – cheap. July 3, 2020. <https://www.businessinsider.co.za/the-us-is-buying-covid-19-drug-remdesivir-like-crazy-a-generic-is-coming-to-sa-cheap-2020-7> Accessed July 19 2020.
16. OpenData South Africa. Essential medicine and master procurement catalogue. <https://odza.herokuapp.com/opendataza/resource/34>. Accessed July 19, 2020.
17. Oanda. Oanda Currency Converter 2020 [Available from: www.oanda.com].
18. Basson A. Coronavirus: SA needs many more ICU beds to be ready for Covid-19 peaks, says Ramaphosa. news24. May 31, 2020. <https://www.news24.com/news24/southafrica/news/coronavirus-sa-needs-many-more-icu-beds-to-be-ready-for-covid-19-peaks-says-ramaphosa-20200531> Accessed July 30, 2020.
19. Acemoglu D, Chernozhukov V, Werning I, Whinston M. Optimal Targeted Lockdowns in a Multi-Group SIR Model. NBER Working Paper No. 27102. Issued in May 2020, Revised in June 2020.

20. Gillenwater S, Rahaghi F, Hadeh A. Remdesivir for the Treatment of Covid-19 - Preliminary Report. *N Engl J Med.* 2020;383.
21. McMahon JH, Udy A, Peleg AY. Remdesivir for the Treatment of Covid-19 - Preliminary Report. *N Engl J Med.* 2020;383.
22. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med.* 2020;8(5):475-81.
23. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA.* 2020.
24. Davies M, Osborne V, Lane S, Roy D, Dhanda S, Evans A, et al. Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment. *Drug Saf.* 2020;43(7):645-56.
25. Olalla J. Remdesivir for the Treatment of Covid-19 - Preliminary Report. *N Engl J Med.* 2020;383.
26. Sun D. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Additional Benefit. *AAPS J.* 2020;22(4):77.
27. Corum J, Wu KJ, Zimmer C. Coronavirus Drug and Treatment Tracker. *New York Times.* https://www.nytimes.com/interactive/2020/science/coronavirus-drugs-treatments.html?fbclid=IwAR0L0oSIhEp8u0mAQiOfc3FRxCYHrBLm23kuq_M80yhVjWTonwn8m2wbsog. Accessed July 17, 2020.
28. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. <https://www.covid19treatmentguidelines.nih.gov/>. Accessed July 17, 2020
29. McCaw ZR, Kim DH, Wei LJ. Remdesivir for the Treatment of Covid-19 - Preliminary Report. *N Engl J Med.* 2020;383.
30. Dodd LE, Follmann D, Wang J, Koenig F, Korn LL, Schoergenhofer C, et al. Endpoints for randomized controlled clinical trials for COVID-19 treatments. *Clin Trials.* 2020:1740774520939938.
31. AS. Remdesivir to be available in South Africa by the end of July. July 8, 2020. https://en.as.com/en/2020/07/08/latest_news/1594223072_744566.html
32. AA. South Africa approves dexamethasone to treat COVID-19. June 20, 2020. <https://www.aa.com.tr/en/africa/south-africa-approves-dexamethasone-to-treat-covid-19/1883532>
33. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet.* 2020;395(10236):1569-78.

Funding: This work was supported by the United States Agency for International Development [72067419CA00004]. Youngji Jo is supported by the Ruth L. Kirschstein National Research Service Award, National Institutes of Health T32 Training Grant (grant number: T32 AI052074-14). Lawrence Long was supported by National Institute of Mental Health (NIMH) of the National Institutes of Health under grant number [1K01MH119923-01A1]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors' views expressed in this publication do not necessarily reflect the views of USAID, the US Government or the National Institutes of Health.

Potential conflicts of interest

B.N., I.S. and L.L. report grants from USAID during the conduct of the study. S.S. reports grants from Wellcome Trust during the conduct of the study. L.L. reports grants from the Bill and Melinda Gates Foundation during the conduct of the study. Other authors have nothing to disclose.